About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Vhltm1Lss
targeted mutation 1, Laura S Schmidt
MGI:2677574
Summary 7 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Vhltm1Lss/Vhltm1.1Lss involves: 129X1/SvJ * C57BL/6 MGI:2677761
cn2
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
either: (involves: 129X1/SvJ * A/J * C57BL/6 * CBA) or (involves: 129X1/SvJ * BALB/c * C57BL/6 * CBA) MGI:3844063
cn3
Vhltm1Lss/Vhltm1Lss
Tg(Gcg-cre)1Slib/0
either: (involves: 129X1/SvJ * A/J) or (involves: 129X1/SvJ * C57BL/6) MGI:3844061
cn4
Vhltm1Lss/Vhltm1Lss
Tg(Ins2-cre)25Mgn/0
either: (involves: 129X1/SvJ * C57BL/6 * DBA) or (involves: 129X1/SvJ * A/J * C57BL/6 * DBA) MGI:3844062
cn5
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
involves: 129S1/Sv * 129X1/SvJ MGI:3653510
cn6
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
involves: 129X1/SvJ * C3H * C57BL/6 MGI:2677759
cn7
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
involves: 129X1/SvJ * C57BL/6 * CBA MGI:3844065


Genotype
MGI:2677761
ht1
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (18 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

reproductive system
• 2-fold reduction in sperm count relative to wild-type

liver/biliary system
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

cellular
• 2-fold reduction in sperm count relative to wild-type

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513




Genotype
MGI:3844063
cn2
Allelic
Composition
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
either: (involves: 129X1/SvJ * A/J * C57BL/6 * CBA) or (involves: 129X1/SvJ * BALB/c * C57BL/6 * CBA)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• numbers of mutant offspring identified at weaning (15.3%) are significantly lower than expected Mendelian numbers (25%)
• expected numbers of double mutant offspring are present embryonically and at birth, but many die by P5




Genotype
MGI:3844061
cn3
Allelic
Composition
Vhltm1Lss/Vhltm1Lss
Tg(Gcg-cre)1Slib/0
Genetic
Background
either: (involves: 129X1/SvJ * A/J) or (involves: 129X1/SvJ * C57BL/6)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Gcg-cre)1Slib mutation (0 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• expected Mendelian numbers of offspring are detected at weaning; no obvious behavioral or physiological abnormalities are detected

endocrine/exocrine glands
N
• pancreases appears histologically normal compared to controls from 10-23 months

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:148174




Genotype
MGI:3844062
cn4
Allelic
Composition
Vhltm1Lss/Vhltm1Lss
Tg(Ins2-cre)25Mgn/0
Genetic
Background
either: (involves: 129X1/SvJ * C57BL/6 * DBA) or (involves: 129X1/SvJ * A/J * C57BL/6 * DBA)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Ins2-cre)25Mgn mutation (2 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• expected Mendelian numbers of offspring are detected at weaning; no obvious behavioral or physiological abnormalities are detected

endocrine/exocrine glands
N
• pancreases appears histologically normal compared to controls from 10-23 months

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:148174




Genotype
MGI:3653510
cn5
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CAG-cre/Esr1*)1Lbe mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (18 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all embryos of pregnant females injected with 2 mg of tamoxifen at E10.5 to inactive Vhlh during mid-gestational stage, die between E14.5 and E15.5

growth/size/body
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls

cardiovascular system
• treatment of pregnant females at E10.5 with tamoxifen results in abnormal vasculature and dilated blood vessels in the body of E14.7 embryos
• dilated vessels are frequently seen after tamoxifen treatment
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• treatment of pregnant females at E10.5 with tamoxifen results in hemorrhage in the dorsolateral region of embryos at E14.5

cellular
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice

embryo
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
• when pregnant females are injected with tamoxifen at E10.5, frequently observe dilated blood vessels and spongiotriophoblast cells in the labyrinthine layer
• dilated vessels are frequently seen after tamoxifen treatment
• thickness of the labyrinthine layer is reduced when pregnant females are injected with tamoxifen at E10.5

liver/biliary system
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos

integument
• seen in embryos of pregnant females injected with tamoxifen at E10.5

homeostasis/metabolism
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly lower serum creatinine levels than tamoxifen-treated control mice (0.24 +/- 0.04 mg/dl versus 0.72 +/- 0.16 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice exhibit significantly lower serum BUN levels than tamoxifen-treated control mice (52.12 +/- 6.61 mg/dl versus 138.10 +/- 13.03 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration

renal/urinary system
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration




Genotype
MGI:2677759
cn6
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
Genetic
Background
involves: 129X1/SvJ * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(ACTB-cre)1Tes mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (18 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice began to die after 3 months of age
• 50% mortalitiy exhibited by 7 months of age
• 90% mortalitiy by 1 year of age

reproductive system
• 30-fold reduction in sperm count relative to wild-type
• abnormal sperm maturation with multinucleated giant cells
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse

neoplasm
• all mice displayed grossly visible hemangiomas by 1 year of age

cardiovascular system
• frequent angiectasis in the liver and with lesser penetrance in the kidneys
• increased vasculature of the pancreas
• no vascular lesions observed in the brain, ovary, or adrenal glands
• limited new blood vessel formation in the liver
• angiogenesis observed the cardiac muscle of 8 of 10 mice examined

liver/biliary system
• livers were irregularly shaped and had vascular lesions containing large, thin-walled vessels filled with blood
• all mice displayed grossly visible hemangiomas by 1 year of age

endocrine/exocrine glands
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse

cellular
• 30-fold reduction in sperm count relative to wild-type
• abnormal sperm maturation with multinucleated giant cells

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513




Genotype
MGI:3844065
cn7
Allelic
Composition
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Vhltm1Lss/Vhltm1Lss Tg(Pdx1-cre)89.1Dam/0 mice develop microcystic adenomas in the pancreas

mortality/aging
• numbers of mutant offspring identified at weaning (3.7%) are significantly lower than expected Mendelian numbers (25%)
• expected numbers of double mutant offspring are present embryonically and at birth, but many die by P5

neoplasm
• at 6-7 months of age, pancreases are indistinguishable from controls; at 16-18 months of age, microcystic adenomas (MCA) are identified; extensive vasculature network is observed in MCA, similar to what is seen in human VHL patients

endocrine/exocrine glands
• at 16-18 months of age, significant loss of exocrine pancreas and replacement with fat deposition is observed
• at 16-18 months of age, some islets appear small and abnormally shaped without many exocrine acinar cells surrounding them
• at 6-7 months of age, pancreases are indistinguishable from controls; at 16-18 months of age, microcystic adenomas (MCA) are identified; extensive vasculature network is observed in MCA, similar to what is seen in human VHL patients
• at 6-7 months of age, pancreases are indistinguishable from controls; at 16-18 months of age, cysts are identified

digestive/alimentary system
• at 16-18 months of age, significant loss of exocrine pancreas and replacement with fat deposition is observed

growth/size/body
• at 6-7 months of age, pancreases are indistinguishable from controls; at 16-18 months of age, cysts are identified

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:148174





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory